In murine HCC models, immune checkpoint inhibitors led to an increase in IDO expression by HCC tumor cells via an IFN-γ-dependent mechanism, and this promoted resistance to single-agent CTLA-4 inhibition and was overcome with IDO inhibitor 1-methyl-D-tryptophan [32]. Here, IDO1 is linked to hepatocellular carcinoma.